Vasculitis
Carol Langford, MD;MHS
Cleveland Clinic
Moreland Hills, Ohio, United States
Disclosure(s): AbbVie: Non-paid consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing), Non-paid consultant (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Ongoing), Non-paid consultant (Ongoing); GlaxoSmithKlein(GSK): Grant/Research Support (Ongoing)
Philip Seo, MD
Johns Hopkins University
Baltimore, Maryland, United States
Disclosure(s): Amgen: Advisor or Review Panel Member (Ongoing)
Although treatment guidelines have become available, many questions persist about their specific application to different clinical scenarios and patient population with ANCA-associated vasculitis (AAV). In addition, recent evidence has reopened the debate about low versus standard dose glucocorticoids. An ongoing controversy about the use of plasmapheresis persists despite the findings of the PEXIVAS study. The use of avacopan has opened an opportunity for glucocorticoid minimization and remaining indications for cyclophosphamide are important to discuss.
Speaker: Carol Langford, MD;MHS – Cleveland Clinic
Speaker: Philip Seo, MD – Johns Hopkins University